{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.3"}]}],"title":"SC Herceptin, <5 minutes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.4"}]}],"title":"SC Herceptin, 6 to 10 minutes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4"}]}],"title":"SC Herceptin, 11 to 15 minutes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4"}]}],"title":"SC Herceptin, 16 to 20 minutes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4"}]}],"title":"SC Herceptin, >20 minutes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"}]}],"title":"SC Herceptin, Not Sure"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1"}]}],"title":"SC Herceptin, Unknown"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1"}]}],"title":"IV Herceptin, <5 minutes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8"}]}],"title":"IV Herceptin, 6 to 10 minutes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8"}]}],"title":"IV Herceptin, 11 to 15 minutes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.3"}]}],"title":"IV Herceptin, 16 to 20 minutes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.1"}]}],"title":"IV Herceptin, >20 minutes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1"}]}],"title":"IV Herceptin, Not Sure"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8"}]}],"title":"IV Herceptin, Unknown"}],"denomUnitsSelected":"HCPs","denoms":[{"counts":[{"groupId":"OG000","value":"235"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"235"}],"units":"HCPs"}],"description":"The time required to perform each method of drug administration was assessed via questionnaire with each HCP by asking to rate the amount of time it took to administer each method of drug administration (IV or SC Herceptin) at the end of the crossover period (Week 24). Time was rated in the following time block categories: less than (\\<) 5 minutes, 6 to 10 minutes, 11 to 15 minutes, 16 to 20 minutes, and greater than (\\>) 20 minutes. Responses of \"Not Sure\" and \"Unknown\" were also allowed. The percentage of HCPs who rated the amount of time in each of the categories was reported.","groups":[{"description":"Participants received Herceptin on Day 1 of each 3-week cycle for 18 cycles, randomized to one of two crossover sequences: SC Herceptin via SID (Cohort 1) or vial (Cohort 2) for Cycles 1 to 4 followed by IV Herceptin for Cycles 5 to 8, or vice versa. In the continuation period, participants received IV Herceptin (Cohort 1) or SC Herceptin (Cohort 2) for up to 10 remaining cycles. Participants in Cohort 1 with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period were offered to self-administer SC Herceptin via SID under the direction of a trained HCP, whereas in Cohort 2, administration was performed by HCP throughout the study. If study treatment for Cycle 1 was IV Herceptin, the initial dose was a loading dose of 8 mg/kg for de novo participants who started Herceptin treatment in the study. For all other cycles where IV Herceptin was given and for non-de novo participants, the dose was 6 mg/kg. The SC dose was 600 mg for both SID and vial.","id":"OG000","title":"All HCPs: SC and IV Herceptin"}],"paramType":"NUMBER","populationDescription":"HCP Population. Results were planned to be analyzed for all HCPs combined because the objective of the study was to compare HCP perceived time savings with use of SC over IV Herceptin.","reportingStatus":"POSTED","timeFrame":"Week 24","title":"Percentage of HCPs by Time Required to Perform Each Method of Drug Administration","type":"SECONDARY","typeUnitsAnalyzed":"HCPs","unitOfMeasure":"percentage of HCPs"}